Elevai Labs, Inc. (ELAB) Key Metrics
ELAB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.2M
- Enterprise value
- −$886,543
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.9
- Price / book
- 0.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.27
ELAB key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsELAB returns How much profit the business earns on the capital it uses.
ELAB financial health Debt, liquidity and how easily interest is covered.
ELAB efficiency & capital use Working capital cycle and where the cash goes.
ELAB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ELAB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ELAB cash returned to shareholders
ELAB key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Share price at fiscal year-end | $355.20 | $13,498.95 | $999,983.16 | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −106.3% | −119.1% | −173.5% | −227.6% | −367.5% | — |
| Return on invested capital (ROIC) | −150.3% | −87.1% | −185.8% | −946.9% | — | — |
| Return on assets (ROA) | −70.5% | −88.1% | −121.5% | −140.7% | −229.7% | — |
| Return on tangible assets | −85.7% | −100.9% | −82.9% | −95.1% | −117.8% | — |
| Free cash flow margin | — | −222.4% | −266.7% | −211.6% | — | — |
| Financial health | ||||||
| Total debt | $2.6M | — | $210,489 | $283,217 | — | $24,000 |
| Cash & short-term investments | $5.4M | $4.0M | $3.3M | $1.2M | $411,858 | $13,351 |
| Net debt | −$2.8M | −$4.0M | −$3.1M | −$871,684 | −$411,858 | $10,649 |
| Debt / equity | 0.34 | — | 0.05 | 0.25 | — | — |
| Debt / assets | 0.21 | — | 0.04 | 0.15 | — | 1.41 |
| Current ratio | 1.74 | 3.36 | 3.79 | 2.64 | 2.95 | 0.42 |
| Quick ratio | 1.72 | 3.36 | 3.41 | 2.25 | 2.21 | 0.42 |
| Interest coverage | -13.5 | -2.5 | -58.4 | -680.2 | — | — |
| Working capital | $2.9M | $4.3M | $3.6M | $963,050 | $420,903 | −$23,589 |
| Invested capital | $5.1M | $2.7M | $710,714 | $259,626 | $38,770 | −$12,940 |
| Tangible asset value | $4.0M | $3.9M | $3.8M | $1.1M | $450,628 | −$23,589 |
| Net current asset value | $1.8M | $3.7M | $3.6M | $790,449 | $420,903 | −$23,589 |
| Capital allocation | ||||||
| Share buybacks (net) | $179 | $0 | — | — | — | — |
| Capex / revenue | 76.0% | 0.4% | 0.7% | 4.6% | 3,927.7% | — |
| Capex / depreciation | 4.06 | 0.71 | 0.96 | 5.46 | 11.78 | 0.00 |
| Stock-based compensation / revenue | −3.2% | 3.9% | 28.5% | 22.4% | 17,213.4% | — |
| R&D / revenue | 24.9% | 4.2% | 0.4% | 29.9% | 14,949.5% | — |
| SG&A / revenue | 275.2% | 34.7% | 196.6% | 225.7% | 76,703.0% | — |
| Efficiency | ||||||
| Days sales outstanding | 107.0 | 3.1 | 5.2 | 3.5 | 459.2 | — |
| Days of inventory on hand | 34.1 | 135.3 | 239,098.7 | 223.7 | 667,025.1 | — |
| Days payables outstanding | 417.4 | 293.3 | 265,839.6 | 176.8 | 203,920.9 | — |
| Cash conversion cycle (days) | -276.4 | -155.0 | -26,735.6 | 50.4 | 463,563.3 | — |
| Receivables turnover | 3.41 | 119.09 | 69.88 | 105.23 | 0.79 | 0.00 |
| Payables turnover | 0.87 | 1.24 | 0.00 | 2.06 | 0.00 | — |
| Inventory turnover | 10.72 | 2.70 | 0.00 | 1.63 | 0.00 | — |
| Asset turnover | 0.05 | 0.35 | 0.48 | 0.60 | 0.00 | 0.00 |
| Average receivables | $172,904 | $20,718 | $24,508 | $7,282 | $1,040 | $371 |
| Average payables | $589,316 | $538,574 | $403,494 | $154,508 | $49,164 | $154 |
| Average inventory | $48,071 | $248,356 | $362,906 | $195,481 | $160,817 | — |
| Intangibles / total assets | 30.1% | 31.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ELAB's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ELAB valuation and financial ratios
Elevai Labs earned a return on equity of −106.3% and a return on invested capital of −150.3% in fiscal 2025. It ended the year with $2.6 million of debt and $5.4 million in cash and short-term investments, a net cash position of $2.8 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the ELAB income statement, the ELAB chart for price history, or the ELAB stock overview for the latest quote and news.
ELAB key metrics FAQ
What is Elevai Labs's return on equity?
Elevai Labs's return on equity (ROE) was −106.3% in fiscal 2025: net income of -$7.7 million on average shareholders' equity of $7.2 million.
What is Elevai Labs's ROIC?
Elevai Labs's return on invested capital was −150.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Elevai Labs have?
Elevai Labs had total debt of $2.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.34 and more cash than debt.
Does Elevai Labs buy back its shares?
Yes. Elevai Labs spent $0.0 million on net share repurchases in fiscal 2025.
What is Elevai Labs's current ratio?
Elevai Labs's current ratio was 1.74 at the end of fiscal 2025: current assets were 1.74 times current liabilities.